Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan designation, according to a post on the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Broadcom (AVGO) Stock Slumps as it Packs its Bags for Chinese Investment Push
- Big pharma fears drug price spikes in US-EU tariff spat, Reuters says
- Oppenheimer biotech analyst holds an analyst/industry conference call
- H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74
- M&A News: AstraZeneca Seals Belgian Firm EsoBiotec Deal to Boost Cell Therapy